Our company was formed in 1972 and completed our 38th year of operations in 2010, with a continued focus on technological innovation, financial strength and market expansion. We are a world leader in developing and delivering innovative medical technology solutions to physicians treating men’s and women’s pelvic health conditions, thereby recognized as a technology leader in the markets we serve. We have built a business that delivers growth fueled by a robust pipeline of innovative products for significant, under-penetrated markets. We have a diverse product portfolio that treats men’s incontinence, erectile dysfunction, and benign prostatic hyperplasia (BPH), and treats women’s incontinence and pelvic floor prolapse. We estimate there are as many as 1.6 billion of these conditions in the global markets we serve, with many people suffering from multiple conditions. Treatment options vary considerably depending on the severity of the condition. Approximately 350 million men and women have conditions sufficiently severe so as to profoundly diminish their quality of life and significantly impact their relationships. Our addressable market is contained within this group of patients. Our product development and acquisition strategies have focused on expanding our product offering for less-invasive solutions for surgeons and their patients, to reduce operating time and trauma, economically benefit the healthcare system, and increase the value of our products to physicians, patients, and payers. Our primary physician customers include urologists, gynecologists, urogynecologists and colorectal surgeons. We continue to make additional investments in support of long-term growth, to expand the market globally and to strengthen our marketing, physician training and regulatory functions outside the U.S.
Company profile
Ticker
AMMD
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
SEC CIK
Corporate docs
IRS number
134018241
Latest filings (excl ownership)
424B3
Prospectus supplement
31 Oct 11
EFFECT
Notice of effectiveness
28 Oct 11
S-4
Registration of securities issued in business combination transactions
14 Oct 11
SC TO-I/A
Issuer tender offer statement (amended)
10 Aug 11
SC TO-I/A
Issuer tender offer statement (amended)
2 Aug 11
15-12G
Securities registration termination
22 Jul 11
SC TO-I
Issuer tender offer statement
1 Jul 11
POSASR
Automatic shelf registration (post-effective amendment)
28 Jun 11
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jun 11
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jun 11